Combination treatment with bortezomib and thiostrepton is effective against tumor formation in mouse models of DEN/PB-induced liver carcinogenesis.

Abstract

Nanoparticle-encapsulated thiazole antibiotic, thiostrepton, has been shown to be an effective agent for inhibiting tumor growth in solid tumor models through the inhibition of proteasomal activity by the induction of apoptosis in cancer cells. Here, we show the efficacy of thiostrepton-micelles in inhibiting tumor growth in a DEN/PB-induced liver cancer model. We also demonstrate an enhanced anticancer effect of the combination treatment of thiostrepton with bortezomib, another proteasome inhibitor in this liver cancer model.

• Authors: Ming Wang, Marianna Halasi, Kasim Kabirov, Aryamitra Banerjee, Jennifer Landolfi, Alexander V Lyubimov, Andrei L Gartel
• Journal: Cell cycle (Georgetown, Tex.) (Cell Cycle) Vol. 11 Issue 18 Pg. 3370-2 (Sep 15 2012) ISSN: 1551-4005 [Electronic] United States
• PMID: 22894930 (Publication Type: Journal Article, Research Support, N.I.H., Extramural)

Chemical References

• Boronic Acids
• Pyrazines
• Diethylnitrosamine
• Bortezomib
• Thiostrepton
• Phenobarbital

Topics

• Animals
• Antineoplastic Combined Chemotherapy Protocols (pharmacology, therapeutic use)
• Boronic Acids (pharmacology, therapeutic use)
• Bortezomib
• Carcinoma, Hepatocellular (drug therapy, pathology)
• Cell Transformation, Neoplastic (drug effects, pathology)
• Diethylnitrosamine
• Disease Models, Animal
• Liver (drug effects, pathology)
• Liver Neoplasms (drug therapy, pathology)
• Mice
• Phenobarbital
• Pyrazines (pharmacology, therapeutic use)
• Thiostrepton (pharmacology, therapeutic use)